Zai Lab Ltd. ADR (ZLAB) Social Stream
ZAI LAB LTD (ZLAB) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ZLAB.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
---|---|---|---|---|---|---|
2021-09-22 | 5 | $225 | $189 | $203.325 | $27.29 | 645.05% |
2021-11-10 | 6 | $225 | $189 | $201.825 | $27.29 | 639.56% |
2021-11-11 | 6 | $225 | $189 | $204.86 | $27.29 | 650.68% |
2021-12-15 | 6 | $225 | $136 | $194.26 | $27.29 | 611.84% |
2021-12-22 | 6 | $217 | $125 | $174.26 | $27.29 | 538.55% |
2022-01-06 | 6 | $217 | $125 | $174.08 | $27.29 | 537.89% |
2022-01-21 | 7 | $217 | $64 | $155.733 | $27.29 | 470.66% |
2022-03-30 | 7 | $217 | $64 | $119.833 | $27.29 | 339.11% |
2022-04-04 | 7 | $217 | $64 | $115.833 | $27.29 | 324.45% |
2022-04-21 | 7 | $217 | $64 | $115.666 | $27.29 | 323.84% |
2022-05-11 | 7 | $217 | $64 | $108.75 | $27.29 | 298.5% |
2022-07-22 | 7 | $193 | $64 | $105.25 | $27.29 | 285.67% |
2022-08-05 | 7 | $193 | $64 | $104.083 | $27.29 | 281.4% |
2022-08-09 | 7 | $199 | $64 | $105.083 | $27.29 | 285.06% |
2022-08-13 | 7 | $199 | $64 | $103.383 | $27.29 | 278.83% |
2022-09-17 | 7 | $199 | $64 | $101.383 | $27.29 | 271.5% |
2022-10-31 | 6 | $199 | $64 | $98.883 | $27.29 | 262.34% |
2022-11-11 | 6 | $127 | $64 | $86.883 | $27.29 | 218.37% |
2022-11-18 | 6 | $127 | $64 | $84.05 | $27.29 | 207.99% |
2023-03-01 | 5 | $127 | $65 | $88.06 | $27.29 | 222.68% |
2023-03-03 | 5 | $127 | $65 | $87.6 | $27.29 | 221% |
2023-05-10 | 5 | $127 | $65 | $85.8 | $27.29 | 214.4% |
2023-05-22 | 5 | $127 | $65 | $86.4 | $27.29 | 216.6% |
2023-06-12 | 5 | $127 | $62.5 | $83.9 | $27.29 | 207.44% |
2023-08-08 | 5 | $127 | $62.5 | $80.3 | $27.29 | 194.25% |
2023-08-09 | 6 | $127 | $45 | $76.8 | $27.29 | 181.42% |
2023-08-14 | 6 | $127 | $40.6 | $74.933 | $27.29 | 174.58% |
2023-08-17 | 6 | $130 | $40.6 | $74.433 | $27.29 | 172.75% |
2023-10-05 | 6 | $130 | $35.3 | $73.55 | $27.29 | 169.51% |
2023-10-26 | 6 | $130 | $35.3 | $73.05 | $27.29 | 167.68% |
2023-11-08 | 6 | $128 | $35.3 | $72.716 | $27.29 | 166.46% |
2023-11-09 | 6 | $123 | $37 | $72.6 | $27.29 | 166.03% |
The Trend in the Analyst Price Target
Over the past 26 months, ZLAB's average price target has gone down $130.72.
Over the past 41 weeks, ZLAB's average upside potential has been 175.01%.
Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
---|---|---|---|---|---|---|
2023-08-08 | 5 | 127 | 62.5 | 80.300 | 24.19 | 231.96% |
2023-08-09 | 5 | 127 | 45.0 | 76.800 | 26.38 | 191.13% |
2023-08-09 | 6 | 127 | 45.0 | 76.800 | 26.38 | 191.13% |
2023-10-26 | 6 | 128 | 35.3 | 72.716 | 22.97 | 216.57% |
2023-11-08 | 6 | 128 | 37.0 | 73.000 | 30.01 | 143.25% |
ZLAB Broker Recommendations Summary
Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
---|---|---|---|---|---|---|
1 | 6 | 0 | 0 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
ZLAB's average broker recommendation rating improved by 0.33 over the prior 23 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In terms of how ZAI LAB LTD fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 3413.5% of that group.
- To contextualize these metrics, consider that out of all US stocks, ZAI LAB LTD's variance in analysts' estimates is lower than -3033% of them.
- To contextualize these metrics, consider that out of stocks in the large market cap category, ZAI LAB LTD's number of analysts covering the stock is higher than 281.31% of them.
- ZAI LAB LTD's average analyst price target is higher than 3310.72% of Pharmaceutical Products stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ZAI LAB LTD are RDY, BGNE, and GSK.
View All Top Stocks by Price Target
Is ZLAB a Buy, Hold or Sell? See the POWR Ratings now!